Transplant Advantage iMDx’s GraftAssure assay with the CM-score demonstrates superior screening performance for kidney transplant patients, with public data showing markedly better positive predictive value than dd-cfDNA alone. This positions iMDx as a compelling partner for high-volume transplant programs seeking more reliable monitoring, and creates priority opportunities with U.S. centers and international sites looking to modernize rejection surveillance. The combination of CLIA/CAP‑accredited in-house testing and access to ongoing real‑world and head‑to‑head data enables faster adoption and tighter integration into clinical workflows.

Commercial Momentum The company is progressing toward commercialization with third‑party head‑to‑head publications, registry engagement, and near‑term expectations of U.S. orders following FDA marketing authorization anticipated later in 2026. EU and APAC demand signals have already surfaced through initial research-use purchases, underscoring a multi‑regional growth trajectory and the need for scalable engagement with hospital systems, distributors, and lab networks.

Partner Ecosystem iMDx is actively building relationships with key opinion leaders and transplant centers, including participation in major congresses and clinical collaborations via the GALACTIC registry. This ecosystem supports co‑development, multi‑site studies, and payer discussions, providing sales teams with credible, data‑driven references to accelerate procurement and expand adoption across institutions.

Global Expansion With a cash balance in the tens of millions and progress toward U.S. commercialization, iMDx is well positioned to scale internationally. Early EU/APAC purchases, plus ongoing real‑world evidence presentations at EFI2026, ERA, and ATC, create opportunities to tailor value propositions for regional regulators, health systems, and pathology labs while establishing global distribution and service capabilities.

Differentiated Value The CM‑Score‑driven approach and published performance claims differentiate GraftAssure from conventional dd‑cfDNA tests, addressing a key buying criterion for transplant programs: accuracy and clinical impact. Combined with in‑house testing capacity, rapid turnaround, and a robust evidence base, this creates a compelling case for pilots or concessional trials aimed at slotting iMDx into standard care pathways and payer coverage discussions.